Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-02-21 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
2021年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2021 Annual Performance Express Announcement" and contains preliminary financial data for the year 2021, including revenue, net profit, earnings per share, and asset information. It explicitly states that the data is preliminary, unaudited, and that the final audited data will be disclosed in the 2021 Annual Report. The document is relatively short (2219 characters) and serves as a quick financial performance update rather than a full comprehensive report. It also includes a risk warning about the preliminary nature of the data. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only, not the full annual report. Therefore, the correct classification is Earnings Release (ER). FY 2021
2022-02-21 Chinese
2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 second extraordinary general meeting of shareholders of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, and detailed voting results on multiple proposals related to a private placement of shares to specific investors, including the issuance plan, pricing, quantity, lock-up arrangements, and related authorizations. The document also references legal compliance and includes lawyer opinions on the meeting's legality. The content is focused on the official voting results and decisions made at the shareholders' meeting rather than the full text of the meeting materials or presentations. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" which covers official results from shareholder votes at any general meeting (AGM or EGM). The document length is substantial and contains detailed voting data, not just a brief announcement or a report publication notice, so it is not an RPA or RNS. Therefore, the correct classification is DVA with high confidence.
2022-02-20 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2022年第二次临时股东大会之法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 second extraordinary general meeting (EGM) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The content focuses on the legality and validity of the meeting and its resolutions, including approval of proposals related to a specific share issuance. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the meeting process and outcomes. It is not an announcement of voting results alone, but a legal opinion letter. Given the nature of the document as a legal opinion on a shareholders meeting, it best fits under Legal Proceedings Report (LTR). The document length is 3367 characters, which is relatively short but contains substantive legal content rather than a mere announcement or certification. Therefore, the classification is LTR with high confidence.
2022-02-20 Chinese
关于注销部分募集资金专项账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the cancellation of a special account for raised funds. It details the background of the fundraising, the management and use of the funds, and the fact that the special account has been fully used and is now being closed. The document is relatively short (1749 characters) and serves as a formal notice about the status and cancellation of a fundraising account rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis. Therefore, it fits best as a Capital/Financing Update (CAP) since it relates to the management and status of capital raised and its dedicated accounts.
2022-02-09 Chinese
关于阿卡波糖片（50mg）获国家药监局签发药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the issuance of a drug registration certificate by the National Medical Products Administration (国家药品监督管理局) for their product Acarbose Tablets (50mg). It details the drug's approval, basic information, and market context. The document is short (1422 characters) and serves as a regulatory announcement about a product approval, not a financial report or management update. It does not contain financial data, management changes, or meeting materials. It is not a report publication announcement since it does not mention the release of a report but rather announces a regulatory approval. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-02-09 Chinese
关于召开2022年第二次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2022 second extraordinary general meeting of shareholders of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), agenda items for shareholder approval including a specific capital raising plan via a private placement of shares, authorization for the board to handle the issuance, and related legal and procedural details. The document is not a report of financial results or an audit, nor is it a transcript or presentation. It is a formal announcement and notice of a shareholders meeting with agenda items for voting, including capital raising proposals. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA) or a Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and agenda for shareholders to vote (not the actual voting results), it aligns best with Proxy Solicitation & Information Statement (PSI). The document length and detail support this classification rather than a short announcement or a full report. Therefore, the filing type is PSI with high confidence.
2022-01-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.